Noiseless High Air Flow Compressor 50K Temperature Rise Oilless Air Compressor for Medical Use

Name: Noiseless High Air Flow Compressor 50K Temperature Rise Oilless Air Compressor for Medical Use
Brand: Sinc Gleeman Medical Technology(Changzhou) Co.,Ltd.
SKU: 1953952235

Jiangsu, ChinaSinc Gleeman Medical Technology(Changzhou) Co.,Ltd.

US$85.00

1-999 Pieces

US$80.00

1,000-2,999 Pieces

US$78.00

3,000-4,999 Pieces

US$75.00

5,000-9,999 Pieces

US$63.00

10,000+ Pieces

Sample price:US$85.00/piece.Request sample

Product profile

Customization

Available

Warranty

Two Years

Lubrication Style

Oil-free

Model NO.

GLE550A-1

Cooling System

Air Cooling

Cylinder Arrangement

Duplex Arrangement

Cylinder Position

Two Air Compressor

Structure Type

Semi-Closed Type

Compress Level

Double-Stage

Refrigerant Type

Oil Free Air Compressor

Brand Name

OEM

Voltage

220V 50Hz

Power

≦550W

Capacity

130L/Min @ 2 Bar

Air Flow Rate

≧130L/Min @ 2 Bar

Speed

1440rpm

Temperature

-5℃-40℃

Thermal Protector

135℃

Noise

≤58dB(a)

Rate Working Pressure

30 Psi ( 2 Bar )

Transport Package

2 Layers Carton Box + Wooden Pallet

Specification

240*113*200 mm

Origin

China

HS Code

8414804990

Production Capacity

200000pieces/Year

Key features

Oil-Free Lubrication: Ensures clean air output suitable for medical applications without oil contamination.

Compact Design: Dimensions of 240*130*200 mm and weight of 10.4 kg for easy portability and installation.

Dual-Stage Compression: Double-stage compression system with duplex arrangement for efficient air flow.

Comprehensive Warranty: Includes a two-year warranty covering mechanical defects for peace of mind.

Company profile

Sinc Gleeman Medical Technology(Changzhou) Co.,Ltd.

Jiangsu, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2020-06-11Nearest Port: ShanghaiAverage Response Time: ≤8.63hTerms of Payment: LC, T/T, D/P, etc.International Commercial Terms(Incoterms): FOB, EXW, CIF, DDP

AI-Powered supplier vetting

SummarySinc Gleeman Medical Technology (Changzhou) Co., Ltd. is identified as both a trading company and manufacturer/factory in China. The supplier reports substantial manufacturing infrastructure, including over 600 employees, a 61,000-square-meter facility, more than 10 production lines, vertical integration, and stated annual capacity of 4,000,000 oil-free air pumps. It exports to multiple regions and holds ISO 9001 and ISO 14001 certifications. The supplier also states that it supports OEM/ODM partnerships. However, many operational, R&D, service, traceability, and contract-related fields remain unknown. An SGS audit is documented with a validity period from June 18, 2024 to June 17, 2025, but the provided audit result code is not interpretable as a substantive performance conclusion.

Supplier typeThe supplier is explicitly classified as both a Trading Company and Manufacturer/Factory. Its stated die-casting, motor production, CNC finishing, automatic assembly, and vertically integrated supply-chain operations support the presence of manufacturing capability rather than trading-only activity.

CertificationsThe supplier reports ISO 14001 and ISO 9001 certification. An SGS audit is also documented, with a stated validity period from 2024-06-18 to 2025-06-17; however, the supplied audit result value is not sufficiently explained to assess the audit outcome.

Production capacityProduction capability is supported by more than 10 production lines, over 600 employees, a 61,000-square-meter factory, full production facilities and testing instruments, vertical integration, and stated annual capacity of 4,000,000 oil-free air pumps. The supplier also reports 3,000,000 oxygen concentrator compressor pieces in annual output information.

Customization capabilityThe supplier explicitly states that it works with global intelligent product brand owners, retailers, and distributors to establish OEM/ODM partnerships. However, the dedicated OEM capability, ODM service availability, and related R&D service fields are otherwise marked unknown, so the evidence confirms stated partnership intent but not the full scope of customization execution.